Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-EDGE TN: Grazoprevir/Elbasvir in Treatment-Naïve HCV
NCT02251990Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of grazoprevir, elbasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Jan 2015; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02251990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251990.